JPMorgan Chase & Co. Has Lowered Expectations for Vera Therapeutics (NASDAQ:VERA) Stock Price

Vera Therapeutics (NASDAQ:VERA) had its price target dropped by equities research analysts at JPMorgan Chase & Co. from $99.00 to $96.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 87.43% from the company’s current price.

Several other analysts have also commented on the company. Wedbush raised their price objective on Vera Therapeutics from $23.00 to $33.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. The Goldman Sachs Group boosted their price target on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research note on Friday. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a report on Friday, December 5th. TD Cowen boosted their price target on shares of Vera Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, December 5th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research report on Wednesday, November 26th. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $74.83.

Vera Therapeutics Price Performance

Shares of VERA stock opened at $51.22 on Friday. The stock has a 50 day moving average price of $33.89 and a 200 day moving average price of $27.28. The firm has a market capitalization of $3.27 billion, a P/E ratio of -12.84 and a beta of 1.21. The company has a debt-to-equity ratio of 0.19, a quick ratio of 12.21 and a current ratio of 12.21. Vera Therapeutics has a 52-week low of $18.53 and a 52-week high of $51.72.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($1.26) EPS for the quarter, missing the consensus estimate of ($1.20) by ($0.06). During the same quarter in the previous year, the firm posted ($0.85) earnings per share. As a group, sell-side analysts predict that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In other news, Director Patrick G. Enright bought 5,882 shares of the business’s stock in a transaction on Thursday, December 11th. The stock was purchased at an average cost of $42.50 per share, for a total transaction of $249,985.00. Following the completion of the transaction, the director directly owned 5,882 shares of the company’s stock, valued at approximately $249,985. This trade represents a ∞ increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Joseph R. Young sold 15,000 shares of the company’s stock in a transaction on Tuesday, November 11th. The shares were sold at an average price of $29.06, for a total value of $435,900.00. Following the sale, the senior vice president directly owned 47,839 shares of the company’s stock, valued at approximately $1,390,201.34. This represents a 23.87% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 16.30% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Quantbot Technologies LP bought a new stake in Vera Therapeutics in the 2nd quarter valued at $51,000. Quarry LP lifted its stake in shares of Vera Therapeutics by 25.0% in the 1st quarter. Quarry LP now owns 2,500 shares of the company’s stock valued at $60,000 after purchasing an additional 500 shares during the period. AlphaQuest LLC increased its stake in shares of Vera Therapeutics by 404.7% in the 1st quarter. AlphaQuest LLC now owns 4,007 shares of the company’s stock valued at $96,000 after acquiring an additional 3,213 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock worth $98,000 after purchasing an additional 539 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its position in shares of Vera Therapeutics by 192.9% during the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company’s stock worth $99,000 after purchasing an additional 2,757 shares during the period. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.